Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 2 2Neuroma, Acoustic 1Neurilemmoma 1Meningioma 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HDAC-42 × 1 year × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated
25 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡